Nutrition and Exercise Before, During, and After Breast Cancer With Neil Iyengar, MD

Proper nutrition and adequate exercise can be considerably effective not only in helping to relieve symptoms and enhance quality of life in patients who have been diagnosed with breast cancer, but also to possibly prevent the development and progression of breast and other cancers. Neil Iyengar, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, has performed extensive research regarding the link between metabolic health and the development and recurrence of breast cancer, a top...
Continue reading

Floxuridine Plus Gemcitabine and Oxaliplatin: Promising Results for Unresectable IHC

With a median overall survival of only 11 months, intrahepatic cholangiocarcinoma (IHC) warrants more effective therapies. Researchers recently discovered that a regimen of hepatic arterial infusion of floxuridine plus systemic gemcitabine and oxaliplatin produces promising outcomes in patients with unresectable IHC. In this phase 2 clinical trial, 38 patients with histologically confirmed, unresectable IHC were enrolled and treated. Participants with resectable metastatic disease to regional ly...
Continue reading

Finding Solutions in Advanced NSCLC Without Driver Mutations: Jamie E. Chaft, MD

​Many patients with non-small cell lung cancer (NSCLC) present with advanced disease, which is highly resistant to chemotherapy. Recently, the use of tumor histology and relevant molecular biomarkers in determining optimal treatment strategies has improved outcomes for some patients, yet a number of targeted therapies are not applicable to patients without driver mutations. In this interview with i3 Health, Jamie E. Chaft, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center and an...
Continue reading

Lenvatinib Plus Pembrolizumab Approved for Advanced Endometrial Carcinoma

The FDA has approved lenvatinib (Lenvima®, Eisai) plus pembrolizumab (Keytruda®, Merck) for patients with advanced endometrial carcinoma who experience disease progression after at least one prior systemic therapy but are ineligible for curative surgery or radiation. Lenvatinib/pembrolizumab is indicated for patients whose cancer is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). "Lenvatinib is a multikinase inhibitor of VEGFR1, VEGFR2, and VEGFR3, and other rece...
Continue reading

Perioperative Chemotherapy, a New Approach to Pancreatic Cancer: An Interview With Alice C. Wei, MD, MSc

The most common type of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC) has limited treatment options and a low survival rate. Traditionally, patients whose disease is resectable—able to be removed by surgery—have been treated with a post-operative adjuvant approach, consisting of surgery followed by chemotherapy or radiation. In recent years, however, there has been a heightened interest in perioperative treatment, in which patients receive chemotherapy or radiation both before and a...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.